This site is intended for healthcare professionals

EU approves Nubeqa for castration-resistant prostate cancer .- Orion + Bayer

Read time: 1 mins
Published:31st Mar 2020
The European Commission has granted marketing authorisation in the European Union (EU) for Nubeqa (darolutamide), an oral androgen receptor inhibitor (ARi), from Orion Corporation and Bayer.
Condition: Prostate Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest